Trials / Completed
CompletedNCT01991821
European Phase III Study of APD421 in PONV
Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Prophylaxis Against Post-operative Nausea and Vomiting
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 368 (actual)
- Sponsor
- Acacia Pharma Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A comparison of the efficacy of APD421 and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APD421 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2014-01-01
- Completion
- 2014-01-01
- First posted
- 2013-11-25
- Last updated
- 2019-08-20
- Results posted
- 2019-08-02
Locations
2 sites across 2 countries: France, Germany
Source: ClinicalTrials.gov record NCT01991821. Inclusion in this directory is not an endorsement.